The guidance, if finalized, would be the first to cover AI devices from design and development to post-market monitoring and risk management, according to a Jan. 6 news release from the agency.
The guidance highlights key areas, including strategies to address transparency, bias and performance monitoring.
The FDA has authorized more than 1,000 AI-enabled medical devices and the new guidance builds on previous efforts.
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.